The reiteration of a Buy rating and a maintained price target of $6 by a reputable analyst like Ed Arce could lead to increased investor confidence in Iterum Therapeutics. This positive analyst coverage is likely to have a favorable impact on the stock price in the short term, as it may influence investor perception and encourage buying activity.